Back

Targovax ASA: Annual Report 2020

On 17 February 2021, the Board of Directors of Targovax ASA approved the Company’s financial statements for 2020, which will be processed at the Company’s annual general meeting on 17 March 2021. The Company’s annual accounts for the financial year 2020, including the financial statements and annual report for the financial year 2020, are together with the auditor’s report attached to this notice. The documents are also available at the Company’s website, www.targovax.com

Targovax Annual Report 2020.pdf

***

For further information, please contact:

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: 

Media enquires:

Andreas Tinglum – Corporate Communications (Norway)
Phone: +47 9300 1773
Email: 

IR enquires:

Kim Sutton Golodetz – LHA Investor Relations (US)
Email: 
Phone: +1 212-838-3777

About Targovax

Activating the patient’s immune system to fight cancer
Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors. Targovax aims to unlock greater clinical benefits in cancer patients by deploying multifunctional platforms to target key immune regulators and oncogenic drivers. Targovax’s focus is to “activate the patient’s immune system to fight cancer”, thus extending and transforming the lives of cancer patients with targeted therapeutic cancer immunotherapies. Targovax’s pipeline aims at different cancer indications, including melanoma, mesothelioma and colorectal cancer. The products are designed to harness the patient’s own immune system to fight the cancer, whilst also delivering a favorable safety and tolerability profile.

Targovax’s lead product candidate, ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system to fight the cancer. On the back of very encouraging data in several indications, in monotherapy and in multiple combination, the next development steps for ONCOS-102 will involve a clinical trial with registration intent in checkpoint inhibitor refractory melanoma.